Citi

For the nine months through September, Morgan Stanley topped the Asia ex-Japan ex-onshore China ECM bookrunning league table with $9.41bn in deals, according to Dealogic. It was also the only bank with double-digit market share.

After a day of caution on Wednesday, when some issuers held back from the primary market after spates of volatility last week, unrated Air France-KLM timed its €400m deal right, showing that investors will still play for yield in higher risk names.

Saxony-Anhalt increased the size of a new three year dollar deal on Wednesday after squeezing pricing tighter twice during two days of marketing.

Automotive component manufacturer Endurance Technologies has opened books for its Rp11.6bn ($173.4m) IPO in India on solid footing, raking in orders from 24 anchor investors.

GDS Holdings, which is heading to the US to go public, has begun premarketing its IPO, with bookbuilding expected in the next two weeks, according to a source close to the transaction.

India’s UPL Corp opened books for its inaugural G3 bond on Wednesday. It is the only deal to have launched so far this week in Asia ex-Japan with China on a one-week holiday to celebrate its National Day.

Samsung BioLogics Co has started gauging investor interest for an up to W2.25tr ($2bn) IPO on the main Kospi board in South Korea, with bookbuilding set to begin in mid-October.

Philippines' International Container Terminal Services (ICTSI) and Hong Kong’s ITC Properties Group are readying their respective dollar-denominated bonds, with both companies on the road to meet with investors this week.

Clio Cosmetics Co is eyeing a listing on the Kosdaq to raise up to W184.4bn ($165m), with bookbuilding set to begin in October.

Thailand-based Kasikornbank’s Hong Kong branch and Malaysia’s RHB Bank navigated a crowded Asia bond market to bag a combined $900m.

Debut issuer Jubilant Pharma ventured out to the international bond market on September 29, netting $300m from its first dollar-denominated transaction.

The names of banks backing Indian firm Intas Pharmaceutical’s bid for the UK and Ireland assets of Teva Pharmaceutical Industries have emerged.